Owlstone’s Breath Biopsy featured in The Economist

SBRI Healthcare alumni and Cambridge-based Owlstone Medical had its Breath Biopsy platform and its inclusion in the GSK’s Phase II Respiratory Disease clinical trial featured in The Economist’s Science and Technology section.

The article discusses other trials of which the Breath Biopsy is a part of, including LuCID, currently recruiting 4,000 patients across Europe to develop a test for the early detection of lung cancer; a collaboration with Warwickshire NHS Trust for the detection of early-stage colorectal cancer in 1,400 people; and evaluation by Cancer Research UK into early detection of a list of cancers using the breathalyser.

SBRI Healthcare has been supporting Owlstone since 2014 and its Breath Biopsy platform as a way to non-invasively screen for early stage lung cancer.

To read more, see The Economist article here.

, , , ,
Posted in: News
 
© Eastern AHSN